19P Stock Chart & Stats
€10.10
€0.25(2.66%)
At close: 4:00 PM EDT
€10.10
€0.25(2.66%)
Day’s Range― - ―
52-Week Range€6.85 - €20.30
Previous CloseN/A
Volume0.00
Average Volume (3M)3.00
Market Cap
€598.41M
Enterprise Value€665.23M
Total Cash (Recent Filing)€72.94M
Total Debt (Recent Filing)€67.95M
Price to Earnings (P/E)62.8
Beta0.74
Next Earnings
Dec 09, 2026EPS Estimate
0.11Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.17
Shares Outstanding62,070,946
10 Day Avg. Volume0
30 Day Avg. Volume3
Financial Highlights & Ratios
PEG Ratio-3.35
Price to Book (P/B)2.38
Price to Sales (P/S)1.67
P/FCF Ratio11.85
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€11.90Price Target Upside17.82% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering11
EPS Forecast (FY)0.26
Revenue Forecast (FY)€459.68M
Bulls Say, Bears Say
Bulls Say
Cash GenerationStrong and rising operating and free cash flow indicate that Phreesia’s platform is increasingly converting revenue into internally generated funds. If sustained, this improves financial resilience, supports product investment, and gives management greater flexibility to reduce debt without relying heavily on external capital.
Profitability InflectionThe shift from substantial historical losses to positive earnings, alongside gross-margin expansion, signals improving operating economics as the business scales. Although margins remain early-stage, this inflection can create durable earnings leverage if customer growth and cost discipline continue over the next several quarters.
Client Expansion And MonetizationPhreesia is expanding both the number of provider customers and revenue generated per customer, supporting a durable two-part growth model. More locations and deeper platform usage can broaden the network, increase recurring provider revenue, and improve the foundation for life-sciences engagement programs.
Bears Say
Thin ProfitabilityDespite the recent earnings inflection, Phreesia’s profit margins remain narrow relative to its revenue base. Small changes in growth, pricing, or operating costs could therefore materially affect net income, limiting the cushion available if execution weakens during the next two to six months.
Provider Economic StrainProvider financial pressure may constrain customers’ willingness to expand software usage or accept higher prices. Deliberate pricing moderation can support retention and downstream network growth, but it may also limit near-term revenue per client and place greater importance on volume and adoption.
Historical Cash-Flow VolatilityRecent cash generation is a clear strength, but the prior period of negative operating cash flow shows that conversion has not yet been proven across business cycles. Sustaining positive cash flow remains important because renewed volatility could reduce funding available for investment and debt reduction.
Phreesia News
19P FAQ
What was Phreesia’s price range in the past 12 months?
Phreesia lowest stock price was €6.85 and its highest was €20.30 in the past 12 months.
What is Phreesia’s market cap?
Phreesia’s market cap is €598.41M.
When is Phreesia’s upcoming earnings report date?
Phreesia’s upcoming earnings report date is Dec 09, 2026 which is in 58 days.
How were Phreesia’s earnings last quarter?
Phreesia released its earnings results on Sep 02, 2026. The company reported €0.027 earnings per share for the quarter, missing the consensus estimate of €0.076 by -€0.049.
Is Phreesia overvalued?
According to Wall Street analysts Phreesia’s price is currently Undervalued.
Does Phreesia pay dividends?
Phreesia does not currently pay dividends.
What is Phreesia’s EPS estimate?
Phreesia’s EPS estimate is 0.11.
How many shares outstanding does Phreesia have?
Phreesia has 62,070,946 shares outstanding.
What happened to Phreesia’s price movement after its last earnings report?
Phreesia reported an EPS of €0.027 in its last earnings report, missing expectations of €0.076. Following the earnings report the stock price went down -4.412%.
Which hedge fund is a major shareholder of Phreesia?
Currently, no hedge funds are holding shares in DE:19P
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Phreesia Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€11.90 (17.82% Upside)
€11.90 (17.82% Upside)
Blogger Sentiment
Neutral
DE:19P Sentiment 83%
Sector Average 67%
Sector Average 67%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-54.65%
12-Months-Change
Fundamentals
Return on Equity
3.01%
Trailing 12-Months
Asset Growth
58.33%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Phreesia
Phreesia, Inc. offers a comprehensive, cloud-based software-as-a-service (SaaS) and payment platform specifically designed for the healthcare industry in the United States and Canada. Its flagship Phreesia Platform streamlines the patient intake process and facilitates integrated patient payment processing. The platform is accessible via multiple modalities, including Phreesia Mobile (a patient-facing mobile application), Phreesia Dashboard (a web-based portal for healthcare clients), self-service tablets known as PhreesiaPads, and on-site Arrivals Kiosks. The Phreesia Platform integrates a suite of specialized modules: An automated patient self-registration system. A revenue cycle management solution providing insurance verification, point-of-sale payment applications, and cost estimation tools. Access solutions for online appointment scheduling, reminders, and referral tracking. A life sciences solution delivering targeted, clinically relevant marketing content to patients. Additionally, a clinical support solution gathers clinical intake and patient-reported outcome (PRO) data across approximately 25 specialties, and enables healthcare clients to communicate with patients via surveys, announcements, text and email messaging, and health campaigns. Dedicated COVID-19 support modules assist with vaccine delivery management, identifying vaccine-hesitant individuals, screening for risk factors, facilitating contactless check-in, and managing telehealth visit intake. Phreesia serves a diverse clientele, including individual patients; single and multi-specialty practices, along with health systems; and pharmaceutical, medical device, and biotechnology firms. Established in 2005, the company maintains its headquarters in Raleigh, North Carolina.
19P Company Deck
19P Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call was strongly constructive, with 10% year-over-year revenue growth, substantial adjusted EBITDA expansion, positive net income for the fifth consecutive quarter, continued positive cash flow, more than $23 million of debt reduction, and reaffirmed fiscal 2027 guidance. AccessOne, Provider Connect, the GLP-1 campaign, and AI initiatives showed encouraging momentum. The main challenges were sequential declines tied to payment-processing seasonality, provider economic strain, pricing moderation, and some earlier volume weakness beyond seasonality.View all DE:19P earnings summaries19P Revenue Breakdown
45.91% Subscription and related services
27.90% Payment processing fees
26.19% Network solutions
19P Stock 12 Month Forecast
Average Price Target
€11.90
▲(17.82% Upside)
Technical Analysis
CareCloud
―
Evolent Health
―
Health Catalyst
―
American Well
―
Waystar Holding Corp.
―